Angelman Syndrome – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Angelman syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of Angelman syndrome for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s Angelman syndrome forecast will answer the following questions:
- Of all people with Angelman syndrome, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Angelman syndrome over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts five Angelman syndrome patient populations, as follows:
- Diagnosed prevalent cases.
- Diagnosed prevalent cases with UBE3A mutation of the maternal allele.
- Diagnosed prevalent cases with deletion of a segment of the maternal chromosome 15q11.2-q13.
- Diagnosed prevalent cases with paternal uniparental disomy (pUPD).
- Diagnosed prevalent cases with imprinting defect.
Note: Coverage may vary by country.
